ForPatients
by Roche

Fallopian Tube Cancer Primary Peritoneal Cancer Ovarian Cancer

A Study of the Efficacy and Safety of Bevacizumab in Chinese Women With Newly Diagnosed, Previously Untreated Stage III or Stage IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.

Trial Status	Trial Runs In	Trial Identifier
Completed	1 Countries	NCT03635489 YO40268

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This multicenter, double-blind, 2-arm, randomized study will evaluate the efficacy and safety of bevacizumab plus paclitaxel and caboplatin compared with placebo plus paclitaxel and caboplatin in Chinese participants with newly diagnosed, previously untreated Stage III or Stage IV epithelial ovarian, fallopian tube, or primary peritoneal cancer. Participants whose disease has not progressed after six cycles of paclitaxel and carboplatin with either bevacizumab or placebo will continue treatment with either bevacizumab or placebo until disease progression, unacceptable toxicity, or a maximum of 22 cycles, whichever occurs first.

Hoffmann-La Roche Sponsor	**Phase 3** Phase

NCT03635489 YO40268
Trial Identifiers

Eligibility Criteria:

Gender	Age	Healthy Volunteers
Female	>= 18 Years	No

© 2022 F. Hoffmann-La Roche Ltd